Figure 7.

Efficacy and Spread of Targeted MeV in vivo in the U87mg Model

(A and B) Analysis of oncolytic efficacy in the EGFR/MMP double-positive, s.c. U87mg tumor model in immunodeficient mice. Human xenograft tumor model in SCID Cb17 mice implanted s.c. with U87mg cells. When tumors reached a volume of 30–50 mm³, mice were injected i.t. on 5 consecutive days with indicated viruses or controls. n = 10–11. (A) Tumor volume was monitored and growth of tumors is displayed. Each line represents the tumor burden of one animal. (B) Survival of tumor-bearing animals. Kaplan-Meyer survival plots of treated animals. Log rank test, **p < 0.01 (UV-inactivated versus MV-MMPA1-E.01). (C) Spread of oncolytic viruses throughout tumor tissue as evidenced by expression of the GFP marker protein. Tumors of individual mice were prepared and dissected at the indicated days post treatment. Subsequently, dissected tumors were imaged for GFP fluorescence using an IVIS Spectrum imaging system. Fluorescence intensities are displayed as indicated.